Welcome to our dedicated page for The Oncology Institute news (Ticker: TOIIW), a resource for investors and traders seeking the latest updates and insights on The Oncology Institute stock.
The Oncology Institute, Inc. (Nasdaq: TOI for common stock and TOIIW for redeemable warrants) regularly issues news that reflects its role in value-based community oncology care. Company press releases highlight its efforts to advance specialized, evidence-based cancer treatment in community settings, supported by a multi-state network of clinics and affiliate locations.
News coverage often focuses on operational performance and financial updates, including quarterly financial results, guidance revisions, and discussions of revenue mix across segments such as patient services, dispensary activities, and capitation arrangements. These updates provide context on how the organization’s value-based oncology model translates into reported revenue, gross profit, and non-GAAP measures such as Adjusted EBITDA and Free Cash Flow.
Readers can also expect announcements about clinical and quality milestones. The Oncology Institute has reported results from participation in federal oncology payment models, including Medicare savings and quality scores in the Enhancing Oncology Model, and has described programs like its High Value Cancer Care initiative and 24/7 symptom management support. Other news items cover the launch of disease-focused centers, such as a Lung Cancer Center of Excellence in Florida, and the expansion of pharmacy and dispensary operations.
Corporate governance and leadership developments are another recurring theme. Recent releases have detailed board changes, including director resignations and appointments, as well as promotions within the executive team in areas such as information technology and people operations. The company also issues news about partnerships, for example its collaboration with Ascertain to deploy AI-powered automation for administrative workflows.
Investors and observers who follow TOI and TOIIW can use this news stream to monitor financial guidance, operational initiatives, technology partnerships, and clinical program developments that the company chooses to highlight in its public communications.
The Oncology Institute (NASDAQ: TOI) achieved $1.8 million in Medicare savings during CMS Enhancing Oncology Model Performance Period 3, equal to more than $6,400 per patient episode. This improves on Performance Period 2 savings of $1.1 million ($3,500+ per episode).
TOI earned maximum quality scores on avoidable emergency department visits and hospital admissions for a second consecutive period, driven by its High-Value Cancer Care program, care navigation, Health Care Coach symptom monitoring, and 24/7 symptom management.
The Oncology Institute (NASDAQ: TOI) announced that CEO Dr. Daniel Virnich and CFO Rob Carter will participate in the 25th Annual Needham Healthcare Conference on Wednesday, April 15, 2026, including a fireside chat at 3:45 p.m. ET.
A live webcast of the presentation will be accessible via the company's Investor Relations website.
The Oncology Institute (NASDAQ: TOI) appointed Minh Merchant as Chief Legal Officer effective April 6, 2026. Ms. Merchant will oversee legal, regulatory, compliance and privacy functions to support TOI's scaling as a national oncology platform.
She brings more than two decades of healthcare legal experience, prior general counsel roles at Midi Health, Kyverna Therapeutics, Aspira Women’s Health and McKesson, and a JD from UCLA School of Law.
The Oncology Institute (NASDAQ: TOI) reported Q4 2025 revenue of $142.0M (+41.6%) and full-year 2025 revenue of $502.7M (+27.8%), with gross profit of $76.4M for 2025 (+41.6%).
Q4 adjusted EBITDA was $0.15M, full-year adjusted EBITDA was $(12.4)M, net loss for 2025 was $(60.6)M, and cash totaled $33.6M as of Dec 31, 2025. 2026 guidance: revenue $630–650M, gross profit $97–107M, adjusted EBITDA $0–9M, free cash flow $(15)–5M.
The company expects ~$150M in capitated revenue in 2026 and anticipates Q1 2026 adjusted EBITDA of $(1)M to $(3)M due to seasonality and reimbursement timing.
The Oncology Institute (NASDAQ: TOI) will release fourth quarter and full year 2025 financial results on Thursday, March 12, 2026, followed by a conference call the same day at 5:00 p.m. ET. Investors can join via phone or webcast.
A replay will be available two hours after the call through Thursday, March 19, 2026 using the provided passcode; international dial-in and webcast details are available on the investor relations site.
The Oncology Institute (NASDAQ: TOI) announced executive participation in three investor conferences in March 2026. Presentations include Jefferies Healthcare Services Innovation & Technology Summit and Leerink Global Healthcare Conference on March 9 in Miami, and Oppenheimer MedTech & Services Conference (virtual) on March 16.
Presenters include Dr. Daniel Virnich, CEO, and Rob Carter, CFO; webcasts and replays will be available via the company Investor Relations site.
The Oncology Institute (NASDAQ: TOI) appointed Kim Tzoumakas to its Board of Directors, effective February 23, 2026.
Ms. Tzoumakas brings more than two decades of executive leadership in oncology, pharmacy services and healthcare operations, currently serving as CEO of VytlOne National Pharmacy Services and with prior CEO and board experience.
The Oncology Institute (NASDAQ: TOI) reaffirmed 2025 guidance and provided a preliminary 2026 outlook on Jan 12, 2026. For 2026 the company expects total revenue of $630 million to $650 million, ~28% growth from the 2025 midpoint, including about $150 million of Capitation revenue.
TOI forecasts Adjusted EBITDA of $0 million to $9 million for 2026 (midpoint would be its first full year of Adjusted EBITDA profitability as a public company) and says profitability from newly onboarded delegated contracts will build through 2026 with fuller economics in 2027.
Longer term, TOI targets ~20% annual revenue growth through 2028, expects Capitation and Dispensary to be ~30% and 50% of revenue respectively, and projects margins expanding to the mid-single-digit range by 2028.
The Oncology Institute (NASDAQ: TOI) announced on Jan 9, 2026 the promotions of Rakesh Panda to Chief Information Officer and Nolan Mariano to Chief People Officer.
Panda brings more than 25 years of IT, digital transformation, cybersecurity, and enterprise software experience, with prior leadership roles at Cisco and Infosys; he will lead TOI’s technology strategy, including AI-enablement and enterprise data privacy and security practices. Mariano, with 18 years in people operations, joined TOI in 2022 and will oversee HR Operations, Total Rewards, Learning and Development, and Talent Acquisition.
CEO Dr. Daniel Virnich said the promotions support TOI’s growth and its focus on technology-enabled, value-based community cancer care.
The Oncology Institute (NASDAQ: TOI) announced that Mark Stolper joined its Board of Directors, effective January 2, 2026. Stolper currently serves as Executive Vice President and Chief Financial Officer of RadNet (NASDAQ: RDNT), a role he has held since 2004, and has prior board experience at public and private healthcare companies including 21st Century Oncology Holdings.
The company highlighted Stolper's expertise in capital markets, fundraising, strategic financial planning and payor strategy as supporting TOI's next phase of growth. Stolper commented that he expects TOI to pursue continued growth and profitability while focusing on cost-effective cancer care and improved patient outcomes.